Advanced Search
Korean J Pediatr 2011 March;54(3) :117-122.
Novel influenza A (H1N1) 2009 infection in the pediatric patients with hematologic and oncologic diseases in the Yeungnam region
Seok Jeong Kang (Kang SJ)1, Jae Min Lee (Lee JM)1, Jeong Ok Hah (Hah JO)1, Ye Jee Shim (Shim YJ)2, Kun Soo Lee (Lee KS)2, Hyun Jung Shin (Shin HJ)3, Heung Sik Kim (Kim HS)3, Eun Jin Choi (Choi EJ)4, So Eun Jeon (Jeon SE)5, Young Tak Lim (Lim YT)5, Ji Kyeong Park (Park JK)6, Eun Sil Park (Park ES)7
1Department of Pediatrics, College of Medicine, Yeungnam University, Daegu
2Department of Pediatrics, College of Medicine, Kyungbook National University, Daegu
3Department of Pediatrics,College of Medicine, Keimyung University, Daegu
4Department of Pediatrics, College of Medicine, Daegu Catholic University, Daegu
5Department of Pediatrics, College of Medicine, Pusan National University, Busan
6Department of Pediatrics, College of Medicine, Inje university, Busan
7Department of Pediatrics, College of Medicine, Gyeongsang National University, Jinju, Korea
Corresponding Author: Jeong Ok Hah ,Tel: +82.53-620-3531, Fax: +82.53-629-2252, Email:
Copyright © 2011 by The Korean Pediatric Society
Purpose : Natural history and consequences of the novel 2009 influenza A H1N1 (2009 H1N1) infection in immunocompromised pediatric patients are not yet fully understood. In this study, we investigated the clinical features and outcomes of the 2009 H1N1 infection in pediatric patients with hematological and oncological diseases. Methods : We retrospectively reviewed the medical records of 528 patients who had hematological and oncological diseases and who were treated at 7 referral centers located in the Yeungnam region. Among the 528 patients, 27 with definite diagnosis of 2009 H1N1 infection were the subjects of this study. All patients were divided into the following 3 groups: patients who were receiving chemotherapy (group 1), patients who were immunosuppressed due to a nonmalignant hematological disease (group 2), and patients who were off chemotherapy and had undergone their last chemotherapy course within 2 years from the influenza A pandemic (group 3). Results : All 28 episodes of 2009 H1N1 infection were treated with the antiviral agent oseltamivir (Tamifluc), and 20 episodes were treated after hospitalization. Group 1 patients had higher frequencies of lower respiratory tract infection and longer durations of fever and hospitalization as compared to those in group 2. Ultimately, all episodes resolved completely with no complications. Conclusion : These results suggest that early antiviral therapy did not influence the morbidity or mortality of pediatric patients with hematological and oncological diseases in the Yeungnam region of Korea after the 2009 H1N1 infection. However, no definite conclusions can be drawn because of the small sample size.
Keywords: Influenza A Virus | H1N1 Subtype | Immunocompromised Patients | Hematologic Diseases | Oseltamivir | Child
PDF Links  PDF Links
Full text via DOI  Full text via DOI
  via Pubmed
Full text via PMC  Full text via PMC
via Pubreader  via PubReader
Download Citation  Download Citation
Supplementary Material  Supplementary Material
Register for e-submission
Register here to access the e-submission system of Korean J Pediatr for authors and reviewers.
Manuscript Submission
To submit a manuscript, please visit the Korean J Pediatr e-submission management system at, read the Instructions for Authors, and log into the Korean J Pediatr e-submission system. For assistance with manuscript submission, please contact:
Free archive
Anyone may access any past or current articles without logging in.
Korean Pediatric Society Office
#1606, Seocho World Officetel, 19 Seoun-ro, Seocho-gu, Seoul 137-070, Korea
TEL : +82-2-3473-7305    FAX : +82-2-3473-7307   E-mail:
BrowseCurrent IssueFor Authors and ReviewersAbout
Copyright© The Korean Pediatric Society. All right reserved.